HOLBROOK E. KOHRT ET AL: "Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer", JOURNAL OF CLINICAL INVESTIGATION, vol. 122, no. 3, 1 March 2012 (2012-03-01) , pages 1066-1075, XP055034582, ISSN: 0021-9738, DOI: 10.1172/JCI61226 (B1)

KOHRT HOLBROOK E ET AL: "Immunomodulation of NK Cells through 4-1BB (CD137) to Improve the Anti-Lymphoma Activity of Rituximab: Antibody-Based Anti-Lymphoma Synergy (abstract 422)", BLOOD , vol. 116, no. 21 1 November 2010 (2010-11-01), XP002681291, Retrieved from the Internet: URL:http://abstracts.hematologylibrary.org /cgi/content/abstract/116/21/422?maxtoshow =&hits=10&RESULTFORMAT=&fulltext=immunomod ulation&searchid=1&FIRSTINDEX=0&volume=116 &issue=21&resourcetype=HWCIT [retrieved on 2012-08-03] (B1)

R. HOUOT ET AL: "Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion", BLOOD, vol. 114, no. 16, 15 October 2009 (2009-10-15), pages 3431-3438, XP055034665, ISSN: 0006-4971, DOI: 10.1182/blood-2009-05-223958 (B1)

ROCH HOUOT ET AL: "Immunomodulating antibodies and drugs for the treatment of hematological malignancies", CANCER AND METASTASIS REVIEWS, vol. 30, no. 1, 28 January 2011 (2011-01-28), pages 97-109, XP019885789, KLUWER ACADEMIC PUBLISHERS, DO ISSN: 1573-7233, DOI: 10.1007/S10555-011-9274-3 (B1)

WILCOX RYAN A ET AL: "Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors", JOURNAL OF CLINICAL INVESTIGATION, vol. 109, no. 5, 1 March 2002 (2002-03-01) , pages 651-659, XP002396136, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US ISSN: 0021-9738, DOI: 10.1172/JCI200214184 (B1)

WO-A1-2005/035584 (B1)

H. NARAZAKI ET AL: "CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells", BLOOD, vol. 115, no. 10, 11 March 2010 (2010-03-11), pages 1941-1948, XP055034669, ISSN: 0006-4971, DOI: 10.1182/blood-2008-12-192591 (B1)

WO-A1-2011/071871 (B1)

WO-A1-2012/032433 (B1)

WO-A2-2005/000901 (B1)

Ajay K Gopal ET AL: "A phase I study of PF-05082566 (anti-1-1BB)+rituximab in patients with CD20+NHL", Journal of Clinical Oncology, Annual Meeting, 29 May 2015 (2015-05-29), XP055322904, Retrieved from the Internet: URL:http://meeting.ascopubs.org/cgi/conten t/abstract/33/15 [retrieved on 2016-11-24] (B1)

H. E. KOHRT ET AL: "CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies", BLOOD, vol. 117, no. 8, 24 February 2011 (2011-02-24), pages 2423-2432, XP055034541, ISSN: 0006-4971, DOI: 10.1182/blood-2010-08-301945 (B1)

WO-A1-2006/088447 (B1)